CLOs on the Move

Ultimate Resources Inc

www.ultimateresources.com

 
Ultimate Resources Inc is a Hermosa Beach, CA-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Euro RSCG 4D

Euro RSCG 4D is a New York, NY-based company in the Business Services sector.

John J Christie And Associates

John J Christie And Associates is a Washington, DC-based company in the Business Services sector.

BO ESSENTIALS

BO ESSENTIALS is a Newport News, VA-based company in the Business Services sector.

Harmony Recovery Center

We are a family-oriented team of widely experienced individuals in recovery and treatment. Our journey began in 2015 with a dream of creating a safe and therapeutic environment for people suffering from the life-wrecking disease of addiction, with the opening of our first facility in Florida, Recovery In Tune. Since that time, we have grown to understand the true need for quality, highly individualized, evidence-based treatment programs. we have made it our mission to bring those high-quality services to different areas of the country like the Charlotte, North Carolina area where these services are desperately needed. We specialize in providing compassionate and highly individualized substance abuse treatment that is evidence-based and outcome-driven. We focus on vastly exceeding the frequently low standards of treatment outcomes in our amazing communities of Charlotte, North Carolina area.

Cellerant

Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.